These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 16478684)

  • 1. Pharmacogenomics: an in-house advantage?
    Borchardt PE
    Drug Discov Today; 2006 Jan; 11(1-2):1-3. PubMed ID: 16478684
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacogenomics. Going from genome to pill.
    Service RF
    Science; 2005 Jun; 308(5730):1858-60. PubMed ID: 15976283
    [No Abstract]   [Full Text] [Related]  

  • 3. Regulatory agency consideration of pharmacogenomics.
    Pendergast MK
    Exp Biol Med (Maywood); 2008 Dec; 233(12):1498-503. PubMed ID: 18849547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cautious welcome for FDA pharmacogenomics guidance.
    Katsnelson A;
    Nat Biotechnol; 2005 May; 23(5):510. PubMed ID: 15877053
    [No Abstract]   [Full Text] [Related]  

  • 5. FDA guidance on pharmacogenomics data submission.
    Savage DR;
    Nat Rev Drug Discov; 2003 Dec; 2(12):937-8. PubMed ID: 14756137
    [No Abstract]   [Full Text] [Related]  

  • 6. Pharmacogenomics: will the regulators approve?
    Hodgson J; Marshall A
    Nat Biotechnol; 1998 Mar; 16(3):243-6. PubMed ID: 9528002
    [No Abstract]   [Full Text] [Related]  

  • 7. Legal implications of pharmacogenomics regarding drug trials, drug labeling, and genetic testing for drug prescription: an international approach.
    Mandry T
    Food Drug Law J; 2004; 59(4):519-35. PubMed ID: 15875348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progress in pharmacogenomics and its promise for medicine.
    Blake CA; Sobel BE
    Exp Biol Med (Maywood); 2008 Dec; 233(12):1482-3. PubMed ID: 18849537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The coming pharmacogenomics revolution: tailoring drugs to fit patients' genetic profiles.
    Noah L
    Jurimetrics; 2002; 43(1):1-28. PubMed ID: 17333591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Translation of pharmacogenomics and pharmacogenetics: a regulatory perspective.
    Lesko LJ; Woodcock J
    Nat Rev Drug Discov; 2004 Sep; 3(9):763-9. PubMed ID: 15340386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Establishing clinical utility of pharmacogenetic tests in the post-FDAAA era.
    Evans BJ
    Clin Pharmacol Ther; 2010 Dec; 88(6):749-51. PubMed ID: 21081943
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Issues in bringing new drugs to the market.
    Tracey WR
    Science; 2005 Dec; 310(5753):1425-6; author reply 1425-6. PubMed ID: 16329172
    [No Abstract]   [Full Text] [Related]  

  • 13. New drugs and product approvals from 2000.
    Taylor SE; Gage TW
    Tex Dent J; 2001 Nov; 118(11):1070-81. PubMed ID: 11806330
    [No Abstract]   [Full Text] [Related]  

  • 14. Drug companies accused of stalling tailored therapies.
    Sinha G
    Nat Med; 2006 Sep; 12(9):983. PubMed ID: 16960561
    [No Abstract]   [Full Text] [Related]  

  • 15. Pharmaceutical postmarket review: fact or fiction?
    Schanz SJ
    Food Drug Law J; 2007; 62(3):493-500. PubMed ID: 17915391
    [No Abstract]   [Full Text] [Related]  

  • 16. Is the drought over for pharming?
    Kaiser J
    Science; 2008 Apr; 320(5875):473-5. PubMed ID: 18436771
    [No Abstract]   [Full Text] [Related]  

  • 17. The federal preemption debate in pharmaceutical labeling product liability actions.
    Gross JM; Curry JA
    Tort Trial Insur Pract Law J; 2007; 43(1):35-70. PubMed ID: 18354866
    [No Abstract]   [Full Text] [Related]  

  • 18. Implications of pharmacogenomics for drug development.
    Kirk RJ; Hung JL; Horner SR; Perez JT
    Exp Biol Med (Maywood); 2008 Dec; 233(12):1484-97. PubMed ID: 18849536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prescription for trouble: common drugs, hidden dangers. Tens of people are at risk.
    Consum Rep; 2006 Jan; 71(1):34-9. PubMed ID: 16491527
    [No Abstract]   [Full Text] [Related]  

  • 20. Institute of Medicine's new drug safety report: implications for Canada.
    Cassels A
    CMAJ; 2006 Dec; 175(12):1515-6. PubMed ID: 17146086
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.